Starpharma Up With News, Down With None; Timing Entry Makes Sense
Feb 25th, 2021
Seeking Alpha, a financial market portal featured an update Starpharma, including the European registration of its VIRALEZE™ antiviral nasal spray. To read the full article click here.
Read More
Channel 7 News reports Starpharma's VIRALEZE has been registered in the UK/Europe
Feb 23rd, 2021
Channel 7 News (Melbourne) reports Starpharma's VIRALEZE™ has been registered in the UK/Europe. Watch here.
Read More
Starpharma signs research agreement with MSD
Feb 12th, 2021
The Market Herald reported that Starpharma signed a Research Agreement with Merck & Co., Inc., Kenilworth NJ USA for dendrimer-based Antibody Drug Conjugates (ADCs) utilising Starpharma’s proprietary DEP® technology. Read more here.
Read More
Ausbiz interviews Starpharma CEO Dr Jackie Fairley
Feb 10th, 2021
Finance and market news website AusBiz interviewed Starpharma CEO Dr Jackie Fairley to discuss the global expansion of AstraZeneca’s clinical trial for AZD0466 and their multi-product DEP® licence with Starpharma. She also spoke about the upcoming launch of VIRALEZE in Europe. Watch the interview here.
Read More
Aussie condom antiviral recruited for Covid-19 fight
Feb 4th, 2021
The Australian interviewed Starpharma CEO Dr Jackie Fairley regarding Starpharma’s plans for the European launch of VIRALEZE™ antiviral nasal spray. Read article here.
Read More
Australian-developed COVID nasal spray set to land in Europe
Feb 4th, 2021
Biotech Dispatch reported on Starpharma's launch plans for VIRALEZE™ in Europe. Read the full article here.
Read More
Channel 7 evening news features Starpharma's VIRALEZE
Feb 3rd, 2021
Watch Laurel Irving Channel 7 News (Melbourne) interview Dr Jackie Fairley, CEO of Starpharma about VIRALEZE™ and the need for other COVID-19 preventative tools alongside vaccines.
Read More
Starpharma prepares to launch COVID-killing nasal spray
Feb 2nd, 2021
Alan Kohler spoke with Dr Jackie Fairley, CEO of Starpharma about the launch of its VIRALEZE™ antiviral nasal spray, for the Eureka Report. Listen to the interview here.
Read More
Leading broker names the ASX healthcare shares to buy in 2021
Jan 9th, 2021
The Motley Fool reported that Starpharma has been named by analysts at Bell Potter "one of ASX shares from several industries that they believe are best placed to have a strong 2021".
To read the full article, click here
Read More
Starpharma Viraleze: COVID-19 Nasal Spray Development
Nov 20th, 2020
Seeking Alpha, a financial market portal featured a piece on Starpharma’s latest update on its VIRALEZE™ COVID-19 nasal spray. The article noted the potential of the spray and Starpharma’s latest regulatory developments on this front. To read the full article click here.
Read More
Starpharma (ASX:SPL) banks $5.7M government R&D tax refund
Oct 21st, 2020
The Market Herald reported that Starpharma are to receive a $5.7 million research and development (R&D) tax incentive refund from the Federal Government following the government’s program to support companies taking on R&D that benefits Australia. To watch the full video click here.
Read More
Biotech In Focus In 2020
Oct 16th, 2020
Online financial news platform FN Arena recently published an article which highlighted six biotech ASX-listed companies that have recently been viewed positively by analysts. Starpharma was listed as one such company, stating that Bell Potter had emphasized the company’s strong growth potential. To read the full article click here
Read More
$2B R&D win for biotech, resources
Oct 8th, 2020
Starpharma was featured in an article by Stockhead, an online publication that delivers news on ASX-listed small and mid-cap companies. The piece looked at the Federal Government’s decision to abandon plans to reduce R&D tax refund by $1.8B, and will instead add $200M in value to the incentive. The article noted Starpharma received a $4.9M tax refund in December 2019 for R&D associated with the development of its DEP drug delivery system and VivaGel BV women’s health products.
To read the full article click here.
Read More
Allianz ups Starpharma stake as M&G sells
Oct 8th, 2020
On 8 October, Starpharma was included in the SMH’s live market update which reported Allianz Global Investors had upped its stake in Starpharma after buying close to 10 million additional shares. It added that the fund’s position in the company had risen from 5 to 7.1 per cent. To read the full article click here
Read More
Starpharma is interviewed by Stockhead to give a company overview and provide an update on its COVID-19 nasal spray
Sep 17th, 2020
Stockhead’s Tim Boreham interviewed Starpharma CEO Jackie Fairley for their Health Kick Podcast. Tim reported that Starpharma has gone from strength to strength following progress on its COVID-19 nasal spray. To hear an overview of the company, and update on current development programs and plans for the year ahead, listen to the full episode here
Read More
2GB’s Jim Wilson interviews Starpharma CEO Dr Jackie Fairley
Aug 26th, 2020
2GB radios Jim Wilson interviewed Starpharma CEO Dr Jackie Fairley to get an update on how Starpharma is fast-tracking a nasal spray designed to be used as a preventative measure in the fight against COVID-19.
To listen to the full interview click here.
Read More
ABC News features Starpharma on ‘The Kohler Report’
Aug 26th, 2020
Starpharma was featured on ABC’s finance news segment ‘The Kohler Report’, where Alan Kohler highlighted that Starpharma shares had risen 23% following the Company’s update on its SPL7013-based antiviral nasal spray, which has shown to have potent antiviral activity against COVID-19. The update included that Starpharma has commenced confidential commercial discussions with related parties.
To watch the full report, click here.
Read More
Australian Manufacturing writes about Starpharma identifying a manufacturer of its antiviral nasal spray for COVID-19
Aug 26th, 2020
Starpharma was recently featured in an article by Australian Manufacturing, a leading publication and resource for the manufacturing and industrial sector in Australia. The article noted Starpharma had undertaken a pilot manufacture for its SPL7013 antiviral nasal spray, which has been tested and confirmed to have potent antiviral activity against SARS-CoV-2, the virus that causes COVID-19. The article also highlightsed SPL has identified a manufacturer and are currently compiling documentation in preparation for regulatory submission.
To read the full article click here.
Read More
The Age: Starpharma CEO Dr Jackie Fairley on Australia’s need to turn homegrown research into commercial products
Jul 3rd, 2020
The Age interviewed Starpharma CEO Dr Jackie Fairley about how the COVID-19 pandemic could be the much needed catalyst for the pharmaceutical industry to improve the way they convert important research into commercial products. Dr Fairley also covered Starpharma’s recent activities in response to the pandemic including, the development of a nasal spray product using the antiviral dendrimer, SPL7013.
To read the full interview click here.
Read More
The 7.30 report interviews Starpharma CEO Dr Jackie Fairley
Jun 25th, 2020
The ABC’s 7:30 report interviewed Starpharma CEO Dr Jackie Fairley to discuss the importance of creating COVID-19 preventative products while the world waits for a vaccine to be developed. Dr Fairley discussed how Starparma’s patented dendrimer SPL7013 has shown significant anti-viral activity against SARS-CoV-2 (coronavirus) and how quickly a product using this ingredient could be brought to market given its approval and use in other marketed products.
Watch the full interview click here.
Read More
Ausbiz interviews Starpharma CEO Dr Jackie Fairley
Jun 19th, 2020
Finance and market news website AusBiz interviewed Starpharma CEO Dr Jackie Fairley to discuss the company’s first radiotherapeutic candidate, DEP® lutetium. The candidate showed highly statistically significant anticancer activity, tumour regression and 100% survival in a human prostate cancer model. The interview also covered the company’s latest VivaGel® BV launch in Central and Eastern Europe.
To watch the full interview click here.
Read More
SBS speaks to Starpharma CEO Dr Jackie Fairley on female representation in business
Jun 19th, 2020
A new study using Australian data showed a causal link between female leadership and business performance. Starpharma is one of only 15 ASX300 companies to have a female CEO and Dr Jackie Fairley spoke with SBS about the importance of having senior female leaders in a corporate setting.
For the full interview click here.
Read More
Starpharma CEO Dr Jackie Fairley on Proactive Investors (Canada)
May 18th, 2020
The Canadian arm of finance news network Proactive Investors recently interviewed Starpharma CEO Dr Jackie Fairley to discuss the Company's DEP® portfolio and the recent news that Starpharma is investigating product concepts for proprietary dendrimer SPL7013 in relation to COVID-19.
Watch the full interview here: https://www.youtube.com/watch?v=jqn06bUymDw&feature=youtu.be
Read More
Starpharma CEO Dr Jackie Fairley on ausbiz
May 11th, 2020
Finance and market news website AusBiz co-founders Kylie Merritt and David Koch interviewed Starpharma CEO Dr Jackie Fairley to discuss DEP® irinotecan moving into Phase 2 and how Starpharma is investigating product concepts for SPL7013 in the fight against COVID-19.
To watch the full interview click here
Read More
Australia’s biotech sector tests multiple agents to fight COVID-19
Apr 22nd, 2020
US biotech publication BioWorld noted that a number of Australian biotech companies have been testing agents in the fight against COVID-19, in particular highlighting Starpharma’s SPL7013 which showed significant positive antiviral activity against the SARS-CoV-2 virus.
To read the full article, click here
Read More
Condom gel compound proves effective against COVID-19
Apr 16th, 2020
The Australian Financial Review interviewed Starpharma CEO Dr Jackie Fairley for an article highlighting the company’s finding that its antiviral dendrimer SPL7013 showed significant activity against coronavirus. The article noted SPL7013 is already used in existing and approved products within Starpharma’s VivaGel® portfolio.
To read the full article, click here (paywall).
Read More
Starpharma Reports Positive Results From SARS-CoV-2 Antiviral Testing Of SPL7013
Apr 16th, 2020
NASDAQ covered the news that Starpharma’s VivaGel® active, astodrimer sodium (SPL7013), showed significant antiviral activity against the coronavirus that causes COVID-19. The piece noted the testing was conducted by an external laboratory, 360Biolabs.
To read the full article, click here.
Read More
Starpharma’s SPL7013 Shows Significant Activity Against SARS-CoV-2 (coronavirus)
Apr 16th, 2020
Leading biotech industry portal BioSpace covered Starpharma’s finding that its proprietary dendrimer SPL7013 showed significant activity against SARS-CoV-2, the coronavirus that causes COVID-19. It noted Starpharma will evaluate product concepts and formulation options for SPL7013 which may have potential applications in the prevention and management of COVID-19.
To read the full article, click here
Read More
Starpharma collects milestone payment from AstraZeneca
Feb 13th, 2020
Biotech Dispatch reported that AstraZeneca has paid Starpharma a $4.5 million milestone payment following the successful dosing of the first patient in the phase 1 clinical trial of AZD0466. The article mentioned the long standing partnership between the two companies which is focused on using Starpharma’s DEP® drug delivery platform to enhance AstraZeneca’s medicines.
To read the full article click here
Read More
Starpharma share price charges higher on product launch news
Feb 13th, 2020
The Motley Fool reported a rise in Starpharma’s share price off the back of the announcement that its VivaGel® BV product will be launched in Asia by Mundipharma. The article highlighted that the deal is an important commercial opportunity for Starpharma with the product set to be accessible to more than 1.5 billion women.
To read the full article, click here
Read More
Starpharma tech ready to deliver
Nov 11th, 2019
The Austraian published an interview with Starpharma CEO Dr Jackie Fairley where she discussed the potential of the dendrimer technology, how it is applied to cancer drugs and the potential benefits it provides to patients.
To read the full article, click here. (paywall)
Read More
Dendrimer drug delivery enhances chemotherapy gemcitabine in human pancreatic mode
Nov 1st, 2019
Online pharmaceutical publication Pharma in Focus noted Starpharma’s positive DEP® gemcitabine results in a human pancreatic model, noting it was one of multiple DEP® drugs from the company.
To read the full article, click here.
Read More
Small cap healthcare stocks surge to billion-dollar plays
Sep 30th, 2019
The Australian Financial Review mentioned that Starpharma was in a group of small cap biotech stocks in stage two trials that investors are closely in the next few years.
To read the full article, click here (paywall)
Read More
Starpharma’s VivaGel® BV regulatory approvals continue in Asia
Sep 3rd, 2019
|
Finance News Network reported Starpharma received further regulatory approval in another Asian country for its breakthrough product for bacterial vaginosis, VivaGel® BV. The news follows the first approval in the region announced on 15 August. |
Read the full news coverage here.
Read More
Update on Starpharma’s latest positive interim DEP® trial results, VivaGel® and upcoming milestones
Aug 30th, 2019
|
Online news outlet Boardroom Media interviewed Starpharma CEO Dr Jackie Fairley following the release of its annual report and full-year results. In the interview, Dr Fairley shared the company’s latest DEP® trial results, as well as VivaGel® and upcoming milestones. |
To listen to the full interview, click here.
Read More
Starpharma sees positive results in ovarian cancer treatment
Aug 29th, 2019
|
Online investor news outlet Finance News Network reported Starpharma’s positive results for its novel HER-2 targeted DEP® conjugate (ADC) which outperformed the leading HER-2 ADC, Kadcyla®, in a human ovarian cancer model. |
To watch the full news video, click here.
Read More
Promising efficacy signals for Starpharma’s DEP® trials
Aug 28th, 2019
|
Biotech trade publication noted Starpharma announced promising efficacy signals in its ongoing clinical trials for both DEP® cabazitaxel and DEP® docetaxel. |
To read the full article, click here.
Read More
Starpharma CEO speaks with Alan Kohler on The Constant Investor
Jul 31st, 2019
Starpharma CEO Dr Jackie Fairley speaks with Alan Kohler for online investor publication The Constant Investor, where she discussed the launch of VivaGel BV in Australia and Europe as well as the company’s latest developments in its DEP® portfolio. To listen to the full interview, click here.
Read More
AstraZeneca inks new deal with Starpharma
Jun 4th, 2019
|
Biotech trade publication noted Starpharma signed a new development and option agreement with AstraZeneca to progress the development of a DEP® version of one of AstraZeneca's existing oncology medicines. The news builds on a previous deal between the companies related to a multiproduct licence covering novel oncology drug candidates. |
Read the article here.
Read More
Starpharma signs second oncology agreement with AstraZeneca
Jun 3rd, 2019
|
Online investor news outlet Finance News Network reported on Starpharma’s second oncology agreement with global pharmaceutical giant AstraZeneca, noting that this is for the development of a DEP® version of an undisclosed and existing market oncology drug. |
Read the full article here (requires sign in).
Read More
Starpharma on Channel Nine News (April 22, 2019)
Apr 22nd, 2019
|
Channel Nine News reported on the launch of VivaGel® BV (Fleurstat BVgel) in Australia and noted it was a world first, novel and non-antibiotic treatment developed in Australia. The report noted BV affects 12 percent of Australian women and if left untreated could lead to infertility, early delivery or miscarriage. |
Read the TV news segment here.
Read More
Markets Live: Starpharma shares rise 13 per cent following Australian launch of VivaGel BV
Apr 16th, 2019
|
The Australian Financial Review reported Starpharma’s share price rose 13 per cent following the company’s announcement that VivaGel® BV was launched nationwide in Australia. The article noted this was the first of many launches for the breakthrough BV product. |
Read the full coverage here (paywall)
Read More
Starpharma’s US license for VivaGel® BV covered by Biotech Dispatch
Dec 20th, 2018
|
Biotech Dispatch featured the news that Starpharma had signed a sales and marketing license agreement for VivaGel® BV for the US market with ITF Pharma. The piece highlighted that upon launch, VivalGel® BV will be ITF Pharma’s top priority women’s health product. |
To read the article, click here.
Read More
Starpharma’s $142M+ US license deal for VivaGel® BV featured in Proactive Investors
Dec 20th, 2018
|
Online investor portal Proactive Investors highlighted Starpharma’s VivaGel® BV US license deal with ITF Pharma, worth $142 million plus escalating double digit royalties. The piece noted ITF Pharma’s strong pedigree in women’s health and their high-calibre team. |
To read the article, click here.
Read More
Small Caps publication covers DEP® irinotecan candidate’s positive performance in pancreatic cancer model
Sep 5th, 2018
|
Small Caps, a specialist investment publication, covered the positive news that Starpharma’s DEP® irinotecan showed complete tumour regression and 100% survival in a human pancreatic cancer model. |
Read the full article here.
Read More
Motley Fool ‘Extreme Opportunities’ Advisor Dr Anirban Mahanti covers Starpharma’s 2018 Financial Year Results
Aug 22nd, 2018
Dr Anirban Mahanti, Advisor at Motley Fool writes that FY18 was a “hugely transformative year for Starpharma”, noting the Company’s key milestones including its “smart licensing agreements” and “potentially game-changing pipeline of drugs”. Originally published on Motley Fool and republished with permission. Read the full article here.
Read More
Starpharma: To win big in science, industry needs business-friendly scientists
Jul 31st, 2018
|
The Australian Financial Review covered Starpharma CEO Dr Jackie Fairley’s appearance at the AFR Innovation Summit, noting she highlighted that the biotech sector needs more business-friendly scientists to help hit more ‘home runs’ in medical science. |
Read the full article here (paywall).
Read More
Starpharma CEO Dr Jackie Fairley interviewed by Alan Kohler for The Constant Investor
Jul 16th, 2018
Starpharma CEO Dr Jackie Fairley speaks with Alan Kohler on online investor publication The Constant Investor, where she discussed the company’s dendrimer platform technology. To listen to fully interview, click here. (Note: paywall) Read More
Starpharma CEO Dr Jackie Fairley interviewed by Alan Kohler on Talking Business
Jul 1st, 2018
|
Starpharma CEO Dr Jackie Fairley speaks with Alan Kohler about how the company has taken VivaGel® BV from discovery to market and developed commercial products with its proprietary dendrimer technology platform. |
To listen to the podcast, click here.
Read More
Starpharma CEO Jackie Fairley featured on Qantas’ inflight magazine Travel Insider
Jul 1st, 2018
Starpharma CEO Dr Jackie Fairley was featured in Qantas’ inflight magazine. To read the article, click here.
Read More